Shinkre Bidhan A, Raisch Kevin P, Fan Liming, Velu Sadanandan E
Department of Chemistry, University of Alabama at Birmingham, 901 14th Street South, Birmingham, AL 35294, USA.
Bioorg Med Chem Lett. 2007 May 15;17(10):2890-3. doi: 10.1016/j.bmcl.2007.02.065. Epub 2007 Feb 25.
Twelve analogs of makaluvamines have been synthesized. These compounds were evaluated for their ability to inhibit the enzyme topoisomerase II. Five compounds were shown to inhibit topoisomerase catalytic activity comparable to two known topoisomerase II targeting control drugs, etoposide and m-AMSA. Their cytotoxicity against human colon cancer cell line HCT-116 and human breast cancer cell lines MCF-7 and MDA-MB-468 has been evaluated. Four makaluvamine analogs exhibited better IC(50) values against HCT-116 as compared to control drug etoposide. One analog exhibited better IC(50) value against HCT-116 as compared to m-AMSA. All 12 of the makaluvamine analogs exhibited better IC(50) values against MCF-7 and MDA-MB-468 as compared to etoposide as well as m-AMSA.
已合成了12种美卡鲁胺类似物。对这些化合物抑制拓扑异构酶II的能力进行了评估。结果表明,有5种化合物抑制拓扑异构酶催化活性的能力与两种已知的靶向拓扑异构酶II的对照药物依托泊苷和m-AMSA相当。评估了它们对人结肠癌细胞系HCT-116以及人乳腺癌细胞系MCF-7和MDA-MB-468的细胞毒性。与对照药物依托泊苷相比,4种美卡鲁胺类似物对HCT-116表现出更好的半数抑制浓度(IC50)值。与m-AMSA相比,1种类似物对HCT-116表现出更好的IC50值。与依托泊苷以及m-AMSA相比,所有12种美卡鲁胺类似物对MCF-7和MDA-MB-468均表现出更好的IC50值。